Abstract | BACKGROUND: AIMS: PATIENTS AND METHODS: RESULTS: After a mean follow-up of 4.2 years, treatment with perindopril 8mg/day was associated with a 22.4% reduction in the primary endpoint compared with placebo (p<0.001) in patients with a history of myocardial infarction. Patients with a history of myocardial revascularization showed a 17.3% reduction in the primary endpoint with perindopril versus placebo (p<0.05). In the combined population of patients with a history of myocardial infarction and/or revascularization, treatment with perindopril produced a 22.4% reduction in the primary endpoint compared with placebo (p<0.001). CONCLUSIONS:
|
Authors | Michel E Bertrand, Kim M Fox, Willem J Remme, Roberto Ferrari, Maarten L Simoons |
Journal | Archives of cardiovascular diseases
(Arch Cardiovasc Dis)
Vol. 102
Issue 2
Pg. 89-96
(Feb 2009)
ISSN: 1875-2136 [Print] Netherlands |
PMID | 19303575
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Perindopril
|
Topics |
- Aged
- Angiotensin-Converting Enzyme Inhibitors
(adverse effects, therapeutic use)
- Coronary Artery Disease
(complications, drug therapy, mortality)
- Double-Blind Method
- Europe
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Myocardial Infarction
(etiology, mortality, prevention & control, therapy)
- Myocardial Revascularization
- Perindopril
(adverse effects, therapeutic use)
- Proportional Hazards Models
- Risk Assessment
- Risk Factors
- Secondary Prevention
- Time Factors
- Treatment Outcome
|